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Abstract
The identification of small molecules that inhibit the sequence-
specific binding of transcription factors to DNA is an attractive
approach for regulation of gene expression. Hypoxia-inducible
factor-1 (HIF-1) is a transcription factor that controls genes
involved in glycolysis, angiogenesis, migration, and invasion, all
of which are important for tumor progression andmetastasis. To
identify inhibitors of HIF-1 DNA-binding activity, we expressed
truncated HIF-1A and HIF-1B proteins containing the basic-
helix-loop-helix and PAS domains. Expressed recombinant HIF-
1A and HIF-1B proteins induced a specific DNA-binding activity
to a double-stranded oligonucleotide containing a canonical
hypoxia-responsive element (HRE). One hundred twenty-eight
compounds previously identified in a HIF-1–targeted cell-based
high-throughput screen of the National Cancer Institute 140,000
small-molecule library were tested in a 96-well plate ELISA for
inhibition of HIF-1 DNA-binding activity. One of themost potent
compounds identified, echinomycin (NSC-13502), a small-
molecule known to bind DNA in a sequence-specific fashion,
was further investigated. Electrophoretic mobility shift assay
experiments showed that NSC-13502 inhibited binding of HIF-
1A andHIF-1B proteins to aHRE sequence but not binding of the
corresponding proteins to activator protein-1 (AP-1) or nuclear
factor-KB (NF-KB) consensus sequences. Interestingly, chroma-
tin immunoprecipitation experiments showed that NSC-13502
specifically inhibited binding of HIF-1 to the HRE sequence
contained in the vascular endothelial growth factor (VEGF)
promoter but not binding of AP-1 or NF-KB to promoter
regions of corresponding target genes. Accordingly, NSC-13502
inhibited hypoxic induction of luciferase in U251-HRE cells and
VEGF mRNA expression in U251 cells. Our results indicate
that it is possible to identify small molecules that inhibit HIF-1
DNA binding to endogenous promoters. (Cancer Res 2005; 65(19):
9047-55)
Introduction
Aberrant signaling pathways originating from oncogenic trans-
formation, loss of function mutations, or dysregulation of receptor
tyrosine kinases all converge on transcription factors to generate
the cancer phenotype. Conceivably, there are much fewer
transcription factors than upstream signaling networks that may
be dysregulated in cancer cells and that may represent potential
targets for interfering with their transcriptional program. There-
fore, transcription factors may represent attractive targets for
development of therapeutics (1). However, most of the activities of
transcription factors are mediated by protein-protein interaction
or binding to DNA in a sequence-specific fashion, both of which are
conventionally considered challenging targets for development of
small-molecule inhibitors (2).
Hypoxia-inducible factor-1 (HIF-1), a heterodimer composed of
two subunits, HIF-1a and HIF-1h (also known as aryl hydrocarbon
receptor nuclear translocator), mediates the transcriptional
program to oxygen deprivation (3). Whereas HIF-1h is constitu-
tively expressed in normoxic cells, HIF-1a protein levels are
primarily regulated by intracellular oxygen concentrations (4), by a
mechanism involving hydroxylation of two proline residues,
recognition by the product of the VHL tumor suppressor gene,
ubiquitylation, and proteasomal degradation (5). However, under
normoxic conditions, HIF-1a levels and/or its transcriptional
activity may be induced by alterations that inactivate tumor
suppressor genes, such as p53, PTEN , and VHL , or activate
oncogenes, such as RAS or Src , or by stimulation with growth
factors, such as transforming growth factor-a, insulin-like growth
factor-I/II, and epidermal growth factor (5–11).
HIF-1a and HIF-1h belong to the basic-helix-loop-helix (bHLH)-
PAS family of transcription factors. The basic domain is responsible
for sequence-specific DNA binding, whereas the HLH and the PAS
domains mediate dimerization and stabilization of the complex on
the DNA (12). The DNA-binding site recognized by HIF-1, known
as hypoxia-responsive element (HRE), contains the core sequence
5V-R(A/G)CGTG-3V, which is present in promoters of HIF-1 target
genes. HIF-1 activates the transcription of genes whose products
are involved in crucial aspects of cancer biology, including cell
survival, glycolysis, angiogenesis, migration, and invasion (5).
We report here that echinomycin (NSC-13502) inhibits HIF-1
DNA-binding activity. Interestingly, chromatin immunoprecipita-
tion (ChIP) experiments indicated that NSC-13502 inhibited
binding of HIF-1 to the endogenous HRE of the vascular
endothelial growth factor (VEGF) promoter but not the binding
of activator protein-1 (AP-1) or nuclear factor-nB (NF-nB) proteins
to corresponding promoters. Accordingly, NSC-13502 inhibited
HIF-1–dependent luciferase expression in U251-HRE cells and
hypoxic induction of VEGF mRNA expression in U251 cells. Our
data provide proof-of-principle that it is possible to identify small
molecules that specifically inhibit HIF-1 DNA binding and raise the
attractive possibility that this approach may lead to modulation of
HIF-1–dependent gene expression.
Materials and Methods
Cell culture and reagents. U251 human glioma cells and MCF-7 cells
were maintained in RPMI 1640 containing 5% fetal bovine serum and
Note: Supplementary data for this article are available at Cancer Research Online
(http://cancerres.aacrjournals.org/).
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2 mmol/L glutamine at 37jC in a humidified incubator containing 21% O2,
5% CO2 in air (called normoxic conditions). U251-HRE cells (stably
transfected with pGL2-TK-HRE) and U251-pGL3 cells (stably transfected
with pGL3 vector), described previously (13), were maintained under the
same conditions, except for the addition of 100 Ag/mL G418. For treatment
under hypoxic conditions, dish or plates were placed into a modular
incubator chamber (Billups Rothenberg, Del Mar, CA), flushed for 20
minutes with a mixture of 1% O2, 5% CO2, and 94% N2 (called hypoxic
conditions), and then placed at 37jC in a humidified incubator. Sf9 insect
cells were maintained at 28jC and ambient atmosphere in SF-900 II serum-
free medium (Invitrogen, Carlsbad, CA). Compounds screened were from
the Developmental Therapeutics Program, National Cancer Institute (NCI).
Recombinant proteins and nuclear extracts. The bHLH-PAS domain
of the human HIF-1a cDNA (1,167 bp) was PCR amplified and cloned into
pTriEx4-His tag expression vector. Protein was expressed in Sf9 insect cells
with recombinant baculoviruses, which are prepared by cotransfecting Sf9
cells with pTriEx4-His tag expression vector and BacVector-3000 Triple Cut
Virus DNA using Eufectin transfection reagent (Novagen, Madison, WI) as
per manufacturer’s protocol, and purified by affinity chromatography on
nickel resin columns. The bHLH-PAS domain of the human HIF-1h cDNA
(1,425 bp) was PCR amplified and cloned into pFlag1 expression vector
(Sigma, St. Louis, MO). Protein was expressed in Escherichia coli DH5a cells
and purified by M2 affinity chromatography. Recombinant p65 was
purchased from ActiveMotif (Carlsbad, CA). Recombinant c-Fos/JunD
proteins were kindly provided by Dr. Chuck Vinson [Center for Cancer
Research (CCR), NCI, Bethesda, MD]. Preparation of nuclear extracts from
U251 and MCF-7 cells was as described previously (13).
Hypoxia-inducible factor-1 DNA-binding ELISA. Biotin-labeled double-
stranded DNA oligonucleotide (f30 pmol) encompassing a canonical HIF-1-
binding site was added onto a streptavidin-immobilized ELISA plate (Pierce,
Rockford, IL). Recombinant HIF-1a-bHLH-PAS (10 pmol) and HIF-1h-bHLH-
PAS (6 pmol) were mixed in 50 AL of 1 buffer [25 mmol/L Tris-HCl (pH 7.6),
100 mmol/L KCl, 0.2 mmol/L EDTA, 20% glycerol, 5 mmol/L DTT]. After
preincubation for 5 minutes at room temperature, protein mix was added to
the plate and incubated at room temperature for 1 hour. The protein complex
was detected by anti-His tag monoclonal antibody (Novagen) at a dilution of
1:2,000 and anti-mouse horseradish peroxidase–conjugated antibody (Sigma)
at a dilution of 1:10,000. After incubating all wells with 100 AL TMB substrate
solution (Sigma) for 10 minutes at room temperature, 0.5 mol/L H2SO4
(100 AL) was added and an absorbance was read at 450 nm with a reference
wavelength of 655 nm. The sense strand sequences of the double-stranded
oligonucleotides were wild-type (WT) HRE 5V-GTGCTACGTGCTGCCTAG-3V
and mutant HRE 5V-GTGCTAAAAGCTGCCTAG-3V. The biotin was labeled at
the 5Vend of the sense strand. Oligonucleotide competition experiments were
done with 50 pmol nonbiotinylated oligonucleotides. Compounds were
screened at a concentration of 10 Amol/L.
Electrophoretic mobility shift assay. Recombinant HIF-1a-bHLH-PAS/
HIF-1h-bHLH-PAS, NF-nB (p65), c-Fos/JunD, or nuclear extracts were used
in electrophoretic mobility shift assay (EMSA). The double-stranded
oligonucleotides encompassing the HIF-1-, NF-nB-, or AP-1-binding sites
were labeled with [32P]dCTP using the Klenow enzyme (Invitrogen). EMSA
was done as described (13). Recombinant HIF-1a-bHLH-PAS (10 pmol)
and HIF-1h-bHLH-PAS (6 pmol), 100 ng p65, or 10 pmol c-Fos and 10 pmol
JunD, respectively, were mixed in 40 AL of 1 buffer [25 mmol/L Tris-HCl
(pH 7.6), 100 mmol/L KCl, 0.2 mmol/L EDTA, 20% glycerol, 5 mmol/L DTT,
200 ng calf thymus DNA]. After preincubation for 5 minutes at room
temperature, 1 AL labeled probe (5  104 cpm) was added and incubated on
ice for 20 minutes. The sense strand sequences of the double-stranded
oligonucleotide were WT HRE 5V-GTGCTACGTGCTGCCTAG-3V, mutant
HRE 5V-GTGCTAAAAGCTGCCTAG-3V, NF-nB 5V-AGTTGAGGGGACTTT-
CCCAGGC-3V, AP-1 5V-CTAGTGATGAGTCAGCCGGATC-3V, WT Myc/Max
5V-AGTTGACCACGTGGTCTGGG-3V, and mutant Myc/Max 5V-AGTTGAC-
TAAAAGGTCTGGG-3V. Competition experiments were done with unlabeled
WT or mutant oligonucleotides (100-fold excess). Monoclonal anti-HIF-1a
antibody (NB100-105) from Novus (Littleton, CO) and polyclonal anti-HIF-
1a antibody (H-206) from Santa Cruz Biotechnology (Santa Cruz, CA) were
used in supershift assay.
Chromatin immunoprecipitation assay. ChIP-IT kit was purchased
from ActiveMotif. ChIP assay was done according to the manufacturer’s
protocol. Anti-HIF-1a monoclonal antibody was from Novus and anti-c-Fos
polyclonal antibody (H-125) and anti-p65 polyclonal antibody (C-20) were
from Santa Cruz Biotechnology. For immunoprecipitation, 2 Ag of each
corresponding antibody were used. PCR primer sets were the following:
VEGF promoter, forward 5V-CCTTTGGGTTTTGCCAGA-3V and reverse 5V-
CCAAGTTTGTGGAGCTGA-3V; cyclin D1 promoter, forward 5V-CTACAC-
CCCCAACAAAACCA-3V and reverse 5V-TAACCGGGAGAAACACACCT-3V;
and intercellular adhesion molecule-1 (ICAM-1) promoter, forward 5V-
CGTGATTCAAGCTTAGCCTG-3V and reverse 5V-TTATTTCCGGACTGA-
CAGGG-3V. For each PCR reaction, primer concentration was 10 pmol/
20 AL. Following 32 to 35 cycles of amplification, the PCR products were run
on a 3.0% agarose gel and analyzed by ethidium bromide staining.
Western blot. Cells were washed with ice-cold PBS and lysed by
incubation on ice in lysis buffer containing 50 mmol/L Tris-HCl (pH 7.4), 1%
NP40, 150 mmol/L NaCl, and complete protease inhibitor cocktail (Roche
Diagnostics, Indianapolis, IN). Lysates were centrifuged at 13,000 rpm for
5 minutes at 4jC and the supernatant was used for Western blotting done
as described previously (13). Polyclonal anti-HIF-1a (H-206) antibody and
anti–cyclin D1 antibody (C-20) were from Santa Cruz Biotechnology.
Monoclonal anti-actin (MAB1501) antibodies were purchased from
Chemicon International (Temecula, CA). HIF-1a and cyclin D1 were detec-
ted using a 1:200 dilution of the specific antibody, whereas anti-actin anti-
body was diluted 1:3,000.
DNA thermal melting analysis. Thermal transition curves were
obtained with a Perkin-Elmer Lambda (Boston, MA) 20 spectrophotometer
using a DBP Peltier System. Absorption changes at 260 nm were collected as
a function of temperature. Oligonucleotides were prepared at 0.5 Amol/L in
the presence or absence of 1 Amol/L small molecule in 10 mmol/L Tris
(pH 8.0), 1 mmol/L EDTA. DMSO concentrations were 0.1% and had no
effect on the Tm of the oligonucleotides. Melting temperatures were
calculated using TempLab software provided by Perkin-Elmer. The sense
strand sequences of the double-stranded oligonucleotides used in this assay
were HRE 5V-TACGTGCTTACGTGCTTACGTGCT-3V, NF-nB-binding site
5V-AGGGGACTTTCCCAGGGGACTTTCCC-3V, and AP-1-binding site 5V-
AGTGATGAGTCAGAGTGATGAGTCAG-3V.
Luciferase assay. U251-HRE cells were seeded onto 24-well plate the day
before treatment. Luciferase assay was done as described previously (13).
Luminescence reading was normalized by protein concentration and
expressed as fold relative to the reference sample (untreated normoxic
control). Cytotoxicity was assayed using the sulforhodamine B (SRB) assay
as described previously (14).
Real-time PCR. Total RNA from U251 cells was obtained using RNA Mini
kit (Qiagen, Valencia, CA). Total RNA (1 Ag) was used to perform reverse
transcription-PCR (RT-PCR) using RT-PCR kit (PE Biosystems, Foster City,
CA). To measure human VEGF and HIF-1amRNA expression, real-time PCR
was done as described previously (13). The following primers and probes
were used: human VEGF, forward 5V-TACCTCCACCATGCCAAGTG-3V
and reverse 5V-ATGATTCTGCCCTCCTCCTTC-3V; VEGF probe, 5V-FAM-
TCCCAGGCTGCACCCATGGC-TAMRA-3V; and human HIF-1a, forward
5V-GCAGCTACTACATCACTTTCTT-3Vand reverse 5V-CAGCAGTCTACATGC-
TAAATCA-3V. Detection of 18S rRNA, used as internal control, was pre-
formed using premixed reagents from Applied Biosystems (Foster City, CA).
Detection of VEGF and 18S rRNA was done using TaqMan Universal PCR
Master Mix (Applied Biosystems), whereas HIF-1a detection was done using
SYBR Green PCR Master Mix (Applied Biosystems).
Transcriptional profiling of the effects of hypoxia and echinomycin
treatment on U251 cells. Human 22K oligonucleotide microarrays
(Operon-22K-oligo-V2 from the NCI/CCR Microarray Center) were used
according to protocols published on the mAdB homepage.3 Briefly,
logarithmically growing U251 cells were treated with 20 nmol/L NSC-
13502 for 20 hours under either normoxia or hypoxia. Total RNA was
extracted from these samples using the RNeasy Mini kit (Qiagen); then,
3 http://nciarray.nci.nih.gov
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equal amounts (20 Ag) were reverse transcribed and amino-allyl modified
dUTP was incorporated into control and drug treated samples using the
Fairplay kit (Stratagene, La Jolla, CA). Each cDNA sample was then
chemically coupled to a Cy3 (control) or Cy5 (treated) fluorescently labeled
dye and purified, the two probes were combined, filtered, and blocked, and
the remaining samples were transferred to a prehybridized glass array
under a coverslip. Arrays were hybridized at 42jC for 16 hours, washed
thrice, and dried. Fluorescence was read on a GenePix 4100A microarray
scanner at a wavelength of 635 nm for the Cy5 (pseudo-colored red) and 532
nm for the Cy3 samples (pseudo-colored green). Data were analyzed
through GenePix Pro 4.1 software; then, data and image files were uploaded
to the NCI/CCR Microarray Center mAdB Gateway for storage, analysis, and
multiple array comparisons.
Results
Expression of recombinant hypoxia-inducible factor-1A and
hypoxia-inducible factor-1B proteins and hypoxia-inducible
factor-1 DNA-binding ELISA screening. To develop assays for the
identification of small-molecule inhibitors of HIF-1 DNA-binding
activity, we expressed recombinant HIF-1a-bHLH-PAS-His (HIF-
1a-389) and Flag-HIF-1h-bHLH-PAS (HIF-1h-475) proteins as
described in Materials and Methods (Fig. 1A). EMSA experiments
showed that HIF-1a-389 and HIF-1h-475 recombinant proteins
mediated a specific DNA-binding activity to an oligonucleotide
containing the canonical HIF-1-binding site (HRE), which was
competed for by addition of excess unlabeled WT, but not mutant,
oligonucleotide (Fig. 1B). To screen large number of compounds,
we tested HIF-1a-389 and HIF-1h-475 recombinant proteins in a
DNA-binding ELISA using a biotinylated HRE bound to streptavi-
din plates. Similar to results obtained in EMSA, HIF-1a-389 and
HIF-1h-475 mediated specific DNA-binding activity that was
competed for by addition of excess nonbiotinylated WT, but not
mutated, oligonucleotide (Fig. 1C). One hundred twenty-eight
active compounds from a U251-HRE-based high-throughput screen
of the NCI 140,000 small-molecule library were then tested using
the HIF-1 DNA-binding ELISA. Twenty of 128 compounds inhibited
HIF-1h-389 and HIF-1h-475 DNA-binding activity by >50% relative
to untreated control at the 10 Amol/L concentration (data not
shown). These compounds were further validated in EMSA using
HIF-1a-389 and HIF-1h-475 (HIF-1) proteins; to control for
specificity, c-Fos and JunD (AP-1) and p65 (NF-nB) binding to the
corresponding DNA oligonucleotide consensus sequences was also
tested. EMSA results showed that all 20 compounds inhibited HIF-
1 DNA-binding activity, consistent with results obtained in ELISA.
However, 12 of 20 compounds also inhibited either AP-1 or NF-nB
DNA binding or both, suggesting that these compounds were
nonspecific inhibitors of protein DNA binding (data not shown).
Eight compounds showed a relative specificity for inhibition of
HIF-1 DNA binding (Supplementary Fig. S1).
Identification of echinomycin as a potent inhibitor of
hypoxia-inducible factor-1 DNA-binding activity. Figure 2A
shows the chemical structure of NSC-13502, one of the most potent
compounds identified in the HIF-1 cell-based high-throughput
screen and further validated using DNA-binding assays. ELISA
experiments (Fig. 2B) showed that NSC-13502 potently inhibited
HIF-1a-389 and HIF-1h-475 DNA-binding activity in a dose-
dependent fashion, with almost complete inhibition at 320 nmol/L.
Similar results were obtained in EMSA where NSC-13502 inhibited
in a dose-specific fashion DNA-binding activity induced by HIF-1a-
389 and HIF-1h-475 recombinant proteins (Fig. 2C-a). More
importantly, NSC-13502 up to 10 Amol/L did not inhibit
DNA-binding activities induced by c-Fos and JunD to the corres-
ponding AP-1 DNA-binding sequence (Fig. 2C-b) or the binding of
p65 to the NF-nB consensus sequence (Fig. 2C-c). These results
indicate that NSC-13502 specifically inhibited HIF-1–dependent,
but not AP-1– or NF-nB–dependent, DNA-binding activity. Inter-
estingly, NSC-13502 was originally discovered as a sequence-specific
DNA-binding agent (15), whose sequence specificity encompasses
the core sequence (5V-CGTG-3V) of HRE consensus sequence 5V-R(A/
G)CGTG-3V (12). To further define the mechanism by which NSC-
13502 inhibited HIF-1 DNA-binding activity, we first characterized
the DNA-binding activities to a canonical HRE in U251 cells
cultured under normoxic or hypoxic conditions. As shown in Fig.
2D-a , hypoxia induced a DNA-binding activity to the HRE (lane 2)
that was supershifted (lane 3) or abrogated (lane 4) by two different
anti-HIF-1a antibodies and was competed for by excess of
Figure 1. A, schematic representation of recombinant HIF-1a-bHLH-PAS and
HIF-1h-bHLH-PAS proteins. HIF-1a-389 (amino acids 1-389) protein fused to a
His tag and HIF-1h-475 (amino acids 1-475) protein fused to a Flag tag were
expressed as described in Materials and Methods. B, EMSA: DNA-binding
reactions were carried out by adding recombinant HIF-1a-389 and HIF-1h-475 in
the presence of 32P-labeled oligonucleotide containing a canonical HRE.
Competition experiments were done using 100-fold molar excess of unlabeled
oligonucleotide containing either WT or mutated HRE. C, ELISA: A biotinylated
double-stranded oligonucleotide containing a canonical HRE was bound to
streptavidin-coated plates. Recombinant HIF-1a-389 and HIF-1h-475 were
added to individual wells as described in Materials and Methods. For competition
experiments, f10-fold excess of nonbiotinylated oligonucleotide, either WT or
containing a mutated HRE, was added to the wells before addition of
recombinant proteins.
Echinomycin, an Inhibitor of HIF-1 DNA-Binding Activity
www.aacrjournals.org 9049 Cancer Res 2005; 65: (19). October 1, 2005
 American Association for Cancer Research Copyright © 2005 
 on April 28, 2011cancerres.aacrjournals.orgDownloaded from 
DOI:10.1158/0008-5472.CAN-05-1235
unlabeled WT (lane 5), but not mutated (lane 6), oligonucleotide.
Next, we tested the ability of NSC-13502 to inhibit HIF-1 DNA-
binding activities in nuclear extracts isolated from cells cultured
under hypoxic conditions. Treatment of hypoxic U251 cells with
NSC-13502 had a minimal effect on both constitutive and inducible
HIF-1 DNA-binding activities detected in nuclear extracts (Fig. 2D-b ,
lane 3). In contrast, addition of NSC-13502 to the binding reaction
in vitro completely abrogated HIF-1-dependent DNA-binding
activities detected in nuclear extracts from hypoxic U251 cells
(Fig. 2D-b , lane 4). These results show that NSC-13502 inhibits DNA
binding of endogenous full-length HIF-1a and HIF-1h proteins and
are consistent with the possibility that NSC-13502 inhibits HIF-1
DNA binding by interacting with DNA and not by interfering
with protein-protein interaction. The core sequence of the HRE
(5V-CGTG-3V) is also present in the E-box (5V-CACGTG-3V), which is
the DNA-binding site of the Myc/Max complex, raising the
possibility that NSC-13502 might also inhibit the binding of nuclear
proteins to the E-box. To test this possibility, we did EMSA
experiments using nuclear extracts harvested from untreated MCF-
7 cells and an oligonucleotide containing the E-box. As shown in
Fig. 2D-c , MCF-7 cells showed constitutive DNA-binding activities
(lane 1) to the E-box that were competed for by excess of unlabeled
WT (lane 2), but not mutant (lane 3), oligonucleotide. Interestingly,
addition of NSC-13502 to the DNA-binding reaction completely
abrogated binding of nuclear proteins to the DNA (lane 4),
providing further evidence of the sequence specificity of NSC-13502.
Echinomycin inhibits hypoxia-inducible factor-1 binding to
the hypoxia-responsive element of endogenous vascular
endothelial growth factor promoter. Results shown thus far
indicate that NSC-13502 inhibits HIF-1, but not AP-1 or NF-nB,
DNA-binding activity in vitro by binding DNA in a sequence-specific
fashion. If this assumption were correct, a ChIP assay would show
Figure 2. NSC-13502 specifically inhibits HIF-1 DNA binding to the HRE. A, chemical structure of NSC-13502. B, ELISA: As described in Materials and Methods,
recombinant HIF-1a-389 and HIF-1h-475 were added to individual wells in the presence of increasing concentrations of NSC-13502. C, EMSA: a, as described in
Materials and Methods, recombinant HIF-1a-389 and HIF-1h-475 were added to DNA-binding reactions in the presence of increasing concentrations of NSC-13502 as
indicated. The oligonucleotide used in this experiment contained the 5V-ACGTG-3V consensus sequence. Similar results were obtained using an oligonucleotide
containing the 5V-GCGTG-3V binding site (data not shown). b, EMSA was carried out using recombinant c-Fos and JunD proteins and an oligonucleotide containing a
canonical AP-1-binding site, as described in Materials and Methods, in the presence of excess unlabeled AP-1 oligonucleotide (lane 2) or NSC-13502 (10 Amol/L)
directly added to the binding reaction before addition of recombinant proteins. c, EMSA was done using recombinant p65 protein and a 32P-labeled oligonucleotide
containing a canonical NF-nB-binding site in the presence of excess unlabeled oligonucleotide (lane 2) or NSC-13502 (10 Amol/L) directly added to the binding reaction.
D, EMSA: a, EMSA was done using nuclear extracts harvested from U251 cells cultured under normoxia (lane 1 ) or hypoxic (lanes 2-6 ) conditions for 16 hours.
Monoclonal (lane 3) or polyclonal (lane 4) anti-HIF-1a antibodies were used for supershift assay. Excess WT HRE (lane 5) or mutant HRE (lane 6 ) was added to the
binding reaction for competition assay. b, EMSA was done using nuclear extracts harvested from U251 cells cultured under hypoxic conditions for 16 hours in the
absence (lane 1) or presence (lane 3) of NSC-13502 (1 Amol/L). Excess WT HRE (lane 2 ) or 1 Amol/L NSC-13502 (lane 4) was added to the binding reaction done
using nuclear extracts from hypoxia-treated cells. c, EMSA was done using nuclear extracts harvested from untreated MCF-7 cells. Excess oligonucleotide
containing a WT (lane 2 ) or mutant (lane 3) E-box consensus sequence was added to the binding reaction for competition assay. Lane 4, NSC-13502 (1 Amol/L)
was added to the binding reaction. c, constitutive; I, inducible; ss, supershift.
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whether NSC-13502 inhibited endogenous HIF-1 DNA-binding
activity in cultured cells. To address this question, U251 cells were
treated with hypoxia and desferrioxamine for 6 hours to induce
maximal HIF-1 DNA-binding activity to cognate DNA-binding sites
of endogenous promoters in the absence or presence of NSC-13502
(0.5 Amol/L). As shown in Fig. 3A , HIF-1 DNA-binding activity to the
HRE present at positions947 to939 (5V-TACGTG-3V) of the VEGF
promoter was detected in cells treated with hypoxia and desferriox-
amine. Treatment of U251 cells with NSC-13502 completely
abrogated HIF-1 DNA-binding activity to the VEGF promoter.
Importantly, NSC-13502 did not affect the binding of AP-1 (c-Fos) to
the cyclin D1 promoter or the binding of NF-nB (p65) to the ICAM-1
promoter, transcription factors that were constitutively present in
untreated U251 cells. These results clearly show that NSC-13502
specifically inhibits HIF-1, but not AP-1 or NF-nB, binding activity to
endogenous promoters in cultured cells.
Echinomycin does not inhibit hypoxia-inducible factor-1A
protein accumulation. To rule out the possibility that the
inhibition of HIF-1 DNA-binding activity was dependent on
down-regulation of HIF-1a protein levels, we did Western blotting
analysis in U251 cells treated under normoxic or hypoxic con-
ditions in the presence or absence of NSC-13502 (0.5 Amol/L). As
shown in Fig. 3B , hypoxia induced HIF-1a protein accumulation,
which was slightly increased by addition of NSC-13502. In addition,
cyclin D1 protein levels were not affected by treatment under
hypoxia or with NSC-13502, consistent with data obtained in the
ChIP assay. In conclusion, NSC-13502 does not affect HIF-1a
protein levels and does not have a general effect on other proteins.
DNA melting temperature analysis. NSC-13502 is a small
molecule known to bind DNA in a sequence-specific fashion (15).
Intercalation of small molecules into the double helix is known to
increase the helix melting temperature (16, 17). The extinction
coefficient of DNA bases at 260 nm in the double-helical form is
much less than in the single-stranded form; thus, melting of the helix
leads to an increase in the absorption at this wavelength. The helix to
coil transition temperature can be determined by monitoring the
absorbance of the DNA bases at 260 nm as a function of tem-
perature. To determine whether compound NSC-13502 binds to DNA
in a relatively specific manner to inhibit HIF-1 protein/DNA–binding
activity, we did DNA melting temperature analysis of the double-
stranded HRE, AP-1 and NF-nB oligonucleotides, in the absence or
presence of NSC-13502 (Supplementary Fig. S2). The melting
temperature (Tm) of HRE DNA was increased from 51.5jC to 65jC
(26.2% increase), whereas only a 5.5jC increase for NF-nB binding
and a 5jC increase for AP-1-binding oligonucleotides were observed,
indicating that NSC-13502 exhibits a higher affinity for HRE core
sequence than AP-1- or NF-nB-binding core sequences. These results
were further validated by analysis of the activity of NSC-13502 on
AP-1 and HRE hairpin oligonucleotides using the ethidium bromide
displacement assay. NSC-13502 caused f50% displacement of
ethidium bromide on HRE oligonucleotide at 3 Amol/L, whereas
no significant influence on AP-1 oligonucleotide was observed even
at a concentration of 10 Amol/L (data not shown).
Echinomycin inhibits hypoxia-inducible factor-1–dependent
luciferase expression in U251-HRE cells. We have described
previously U251-HRE and U251-pGL3 cells, which express the
Figure 3. NSC-13502 inhibits HIF-1 binding to the HRE of the VEGF promoter in cultured cells. A, ChIP assay: For VEGF promoter, U251 cells were treated with
hypoxia plus desferrioxamine (400 Amol/L) in the presence or absence of NSC-13502 (0.5 Amol/L) for 6 hours. ChIP assay was done as described in Materials and
Methods using an anti-HIF-1a or irrelevant isotype-matched control antibody, respectively. Input DNA was measured before performing immunoprecipitation and the
sample was then divided between relevant and irrelevant antibodies. PCR fragment of 135 bp from the VEGF promoter is indicated. For cyclin D1 promoter, U251 cells
were cultured under normoxic conditions for 6 hours in the absence or presence of NSC-13502 (0.5 Amol/L). ChIP was done using anti-c-Fos or isotype-matched
irrelevant antibodies, respectively. PCR fragment of 163 bp from the cyclin D1 promoter is indicated. For ICAM-1 promoter, U251 cells were cultured under normoxic
conditions for 6 hours in the absence or presence of NSC-13502 (0.5 Amol/L). ChIP was done using anti-p65 or isotype-matched irrelevant antibodies, respectively.
PCR fragment of 176 bp from the ICAM-1 promoter is indicated. B, Western blot: U251 cells were treated under normoxic (Nor ) or hypoxic (Hyp) conditions for 16 hours
in the absence or presence of NSC-13502 (0.5 Amol/L). Total cell lysates were prepared as described in Materials and Methods. Immunoblotting was done using
polyclonal anti-HIF-1a and polyclonal anti–cyclin D1 antibodies, respectively. Actin was assessed on the same membrane as internal control.
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luciferase reporter gene under control of HIF-1 or SV40 promoters,
respectively (13). To further define the EC50 of NSC-13502 in
inhibiting HIF-1–dependent transcriptional activity, U251-HRE and
U251-pGL3 cells were treated under normoxic or hypoxic
conditions in the presence or absence of increasing concentrations
of NSC-13502. As shown in Fig. 4A , NSC-13502 very potently
inhibited hypoxic induction of luciferase expression in U251-HRE
in a dose-dependent fashion with an EC50 of f1.2 nmol/L. In
contrast, NSC-13502 did not significantly affect luciferase expres-
sion in the U251-pGL3 control cell line under either normoxic or
hypoxic conditions (Fig. 4B). To test whether inhibition of
luciferase expression in U251-HRE was reversible, cells were
treated with NSC-13502 at 5, 10, and 20 nmol/L for 4 hours and
then washed and incubated under normoxic or hypoxic conditions
for 36 hours. As shown in Fig. 4C , 94%, 80%, and 42% of hypoxia-
induced luciferase expression was restored in cells in which
NSC-13502 was washed out after 4-hour treatment at 5, 10, and
20 nmol/L, respectively, indicating that the DNA-binding activity of
NSC-13502 is in fact reversible. To determine whether NSC-13502
had any effect on cell viability at the concentrations used, we did a
SRB assay in U251-HRE cells exposed to increasing concentrations
of NSC-13502. The IC50 under normoxic or hypoxic conditions at 24
hours was >5 Amol/L (data not shown), indicating that NSC-13502
did not have a significant effect on cell viability under our
experimental conditions.
Echinomycin inhibits hypoxic induction of vascular endo-
thelial growth factor mRNA expression. To investigate the
effects of NSC-13502 on VEGF mRNA expression, U251 cells were
treated under normoxic or hypoxic conditions in the absence or
presence of increasing concentrations of NSC-13502 (0-10 nmol/L)
for 16 hours. As shown in Fig. 5A , hypoxia induced a 5-fold
increase in VEGF mRNA expression, which was significantly (P <
0.01) inhibited by addition of NSC-13502 in a dose-dependent
fashion. In contrast, HIF-1a mRNA expression, which was slightly
decreased under hypoxic conditions relative to normoxia, was not
affected by NSC-13502 (data not shown). To further investigate
the global effect of NSC-13502 on gene expression, we did
transcriptional profiling analysis using NCI human microarray
sets, which contain oligonucleotides representing z11,000 genes.
U251 cells were treated under normoxia or hypoxia in the
presence of NSC-13502 (20 nmol/L) for 20 hours. Overall, we
found that more genes were down-regulated than up-regulated, as
Figure 4. NSC-13502 inhibits hypoxic induction
of luciferase expression in U251-HRE cells.
U251-HRE (A) or U251-pGL3 cells (B) were
seeded (2  105 per well) in 24-well plates and
incubated under normoxic or hypoxic conditions
for 16 hours in the presence or absence of the
indicated concentrations of NSC-13502; then,
expression of luciferase was measured. C,
U251-HRE cells (1  105 per well) were seeded
in 24-well plates and treated with the indicated
concentrations of NSC-13502 for 4 hours. Cells
were then washed thrice with medium and
incubated under normoxic or hypoxic conditions
in the presence or absence of the indicated
concentrations of NSC-13502 for 36 hours. Cell
lysates were harvested and luciferase expression
was measured. Results are expressed as fold
change relative to untreated cells cultured under
normoxia condition (equal to 1) after normalization
for protein concentration.
Cancer Research
Cancer Res 2005; 65: (19). October 1, 2005 9052 www.aacrjournals.org
 American Association for Cancer Research Copyright © 2005 
 on April 28, 2011cancerres.aacrjournals.orgDownloaded from 
DOI:10.1158/0008-5472.CAN-05-1235
one might have predicted. In particular, 276 and 451 genes were
down-regulated by z2-fold under normoxic or hypoxic conditions,
respectively, in the presence of NSC-13502 (Fig. 5B). In contrast,
only 186 genes were up-regulated under normoxia and 197 under
hypoxia. Fewer genes were changed by z4-fold, suggesting that
NSC-13502 has a limited effect on global gene expression (Fig.
5B). Notably, more genes were down-regulated under hypoxic
than normoxic conditions (451 versus 276 by z2-fold and 65
versus 36 by z4-fold), consistent with the possibility that NSC-
13502 inhibited preferentially HIF-1–dependent gene expression.
Indeed, we found that several known HIF-1–inducible genes
present on the array, which were up-regulated under hypoxic
conditions, were also significantly decreased in the presence of
NSC-13502. In particular, 17 of 109 genes induced by hypoxia by
>2.5-fold could be identified as HIF-1–inducible genes based on
published results. Fourteen of the 17 HIF-1–inducible genes were
significantly inhibited by NSC-13502 by >3-fold (Table 1).
Moreover, 10 known HIF-1–inducible genes were identified among
the 65 genes inhibited >4-fold by NSC-13502 under hypoxic
conditions. In conclusion, our results show that expression of a
limited number of genes is affected by treatment of U251 cells
with NSC-13502 and they are consistent with a predictable pattern
of inhibition of known HIF-1–inducible genes.
Discussion
HIF-1a is the downstream mediator of hypoxic and nonhypoxic
signaling pathways, which play a crucial role in cancer progres-
sion. HIF-1 induces expression of genes whose products are
involved in cancer cells survival, glycolysis, angiogenesis, migra-
tion, and invasion (5). Notably, HIF-1a is overexpressed in human
cancers due to hypoxia-dependent and/or hypoxia-independent
pathways (6, 18, 19), and overexpression of HIF-1a has been
implicated as a poor prognostic indicator in a variety of tumors
(20–23). Therefore, HIF-1 is an attractive target for cancer therapy
(5, 24, 25).
Several approaches have been used to inhibit HIF-1a expression
and/or activity: antisense or small interfering RNA strategies
(26, 27), inhibition of proteins that modulate HIF-1 activity (28–31),
signal transduction pathways involved in HIF-1a activation
(11, 32, 33), microtubules (34), topoisomerase I (35), or mechanisms
not clearly defined (36, 37). Our group has recently shown that
topotecan, a topoisomerase I poison, inhibits HIF-1a protein
accumulation independently of DNA replication-mediated DNA
damage, suggesting a distinct mechanism of action from the
cytotoxic effects (35). More importantly, we have shown that
topotecan administered on a chronic schedule inhibits HIF-1a
protein accumulation, angiogenesis, and tumor growth in U251-
HRE human glioblastoma xenografts (38). Most of the agents
described above affect targets that are also involved in other
biological functions, which will ultimately determine their
therapeutic activity, and they can be defined nonselective
inhibitors of HIF-1. Although these agents might be useful in the
clinical setting as HIF-1 inhibitors, it remains difficult to clearly
define the contribution of HIF-1 inhibition to their therapeutic
activity and to establish how they should be used in the clinic to
inhibit HIF-1.
In contrast, a selective inhibitor would target a specific step of
HIF-1 activation pathway. Selective inhibitors would be ideal tools
for probing the HIF-1 pathway and to establish the therapeutic
potential of HIF-1 inhibition. Several domains of HIF-1 might be
suitable targets for the development of selective HIF-1 inhibitors:
domains involved in dimerization with HIF-1h, in the recruitment
of coactivators, which are required for maximal transcriptional
activity, or binding to DNA, which is dependent on sequence
specificity. Each of these potential targets has been exploited to
different extents.
One approach has been to interfere with the interaction between
the C-TAD of HIF-1a and the CH1 domain of p300, a coactivator
required for maximal transcriptional activity of HIF-1 (39). This
interaction, which is at least in part dependent on the hydroxylation
of an asparagine residue at position 802, has been targeted with
chetomin, a small molecule that showed therapeutic activity in
HCT116 and PC3 xenograft models (40). This approach, although
attractive, is limited by the unstructured conformation of free HIF-
1a C-TAD (41), which makes more problematic inhibiting its
interaction with p300, and by concerns on the potential lack of
specificity of an active agent.
Synthetic polyamides have been designed that interfere in a
sequence-specific fashion with transcription factors to modulate
their functional activity. Hairpin polyamides and polyamide-
acridine conjugates have been shown to inhibit protein-DNA
complexes in some cases (42, 43). Recently, a synthetic pyrrole-
imidazole polyamide targeting the HRE site in the VEGF
promoter has been described, which was designed to bind to
the DNA sequence 5V-WTWCGW-3V (where W = A or T; ref. 44).
Figure 5. Effect of NSC-13502 on gene expression in U251 cells. A, VEGF
mRNA expression: U251 cells were cultured under normoxic or hypoxic
conditions in the absence or presence of the indicated concentrations of NSC-
13502 for 16 hours. Total RNA was harvested and analyzed for human VEGF
mRNA expression using real-time PCR as described in Materials and Methods.
18S rRNA was tested in parallel as internal control for input RNA. Results
are expressed as fold increase relative to mRNA levels of untreated cells
cultured under normoxic conditions (equal to 1). Columns, average of four
independent experiments; bars, SE. *, P < 0.01, one-way ANOVA. B, microarray
analysis: U251 cells were cultured under normoxic or hypoxic conditions for
20 hours in the absence or presence of NSC-13502 (20 nmol/L). Total RNA was
harvested and processed as described in Materials and Methods. Data were
analyzed through GenePix Pro 4.1 software; then, data and image files were
uploaded to the NCI/CCR Microarray Center mAdB Gateway for storage,
analysis, and multiple array comparisons. The numbers outside the intersections
represent genes affected under hypoxia or normoxia; the numbers inside the
intersections represent genes affected under both hypoxia and normoxia.
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This polyamide blocked HIF-1 DNA binding to the HRE of the
VEGF promoter in vitro and inhibited VEGF mRNA expression
and protein levels in cultured HeLa cells. Although the design of
synthetic polyamides might offer a higher sequence-based
specificity, their development as therapeutics remains to be
further established.
Conceptually, a small molecule with favorable pharmacologic
properties would be more attractive to inhibit HIF-1 DNA binding,
although the identification of a sequence-specific compound that
interferes with DNA binding of transcription factors remains
elusive. We provide here proof-of-principle that NSC-13502 can in
fact inhibit, in a sequence-specific fashion, the binding of HIF-1 to
its cognate DNA-binding sequence.
NSC-13502, a cyclic peptide of the family of quinoxaline
antibiotics that was originally isolated from Streptomyces echinatus
(45), is a small molecule known to bind DNA in a sequence-specific
fashion. The strong binding sites for NSC-13502 contain the central
2-bp sequence 5V-CG-3V, and the key recognition elements for NSC-
13502 are contained in the sequences 5V-ACGT-3Vand 5V-TCGT-3V
(15). In EMSA, NSC-13502 showed a significant degree of specificity
between inhibiting binding of HIF-1 to the HRE, which contains
5V-ACGT-3V in its core sequence, and unrelated sequences recog-
nized by the AP-1 or NF-nB family of transcription factors.
Although the evidence provided by EMSA experiments was
encouraging, it was far from proving that this compound retained
the ability to inhibit endogenous HIF-1a and HIF-1h proteins and
more importantly to block the binding of HIF-1 heterodimer to
endogenous HRE-containing promoters. Two findings reported
here provide a strong support for this conclusion: (a) the ability of
NSC-13502 to block HIF-1 DNA binding of endogenous nuclear
proteins from hypoxic treated cells, but only when the compound
was added directly to the binding reaction, consistent with the
notion that NSC-13502 binds DNA and not HIF-1a and/or HIF-1h
proteins, and (b) the ability of NSC-13502 to block HIF-1 DNA
binding to the HRE of VEGF promoter detected by ChIP. More
importantly, NSC-13502 under the same experimental conditions
did not block the binding of c-Fos to the AP-1 site of the cyclin D1
promoter or the binding of p65 to the NF-nB site of the ICAM-1
promoter. We believe that these results provide strong evidence
that NSC-13502 interferes with HIF-1 DNA binding in a sequence-
specific fashion. It is, however, conceivable that the sequence
specificity of NSC-13502 may not be restricted to HIF-1 but may
include other transcription factors that have similar core-binding
sites in their DNA consensus sequences. One example is the Myc/
Max family of transcription factors, whose DNA-binding site
(E-box, 5V-CACGTG-3V; ref. 46) encompasses the core sequence
5V-CGTG-3V, which is also present in the HIF-1 consensus sequence
and is part of the sequence specificity of NSC-13502. Indeed, we
found that NSC-13502 completely inhibited DNA-binding activities
to an oligonucleotide containing the E-box sequence detected in
nuclear extracts harvested from untreated MCF-7 cells. Although
this feature might detract from the target specificity of this small
molecule, it may also become a desirable element for increased
therapeutic activity.
Consistent with data from the primary high-throughput
screen, NSC-13502 inhibited hypoxic induction of luciferase in
U251-HRE cells and VEGF mRNA expression in U251 cells.
Ultimately, the feasibility of using small molecules to interfere in
a sequence-specific fashion with binding of transcription factors
to DNA will be determined by their ability to modulate gene
expression in a predictable fashion and by their activity in
preclinical studies where validation of the inhibition of the target
and its downstream genes will become essential. Global analysis
of gene expression using oligonucleotide arrays containing
sequences representing f11,000 human genes showed that a
relatively small number of genes are changed by addition of
NSC-13502 under either normoxic or hypoxic conditions. In fact,
addition of NSC-13502 to U251 cells cultured under normoxic
conditions only down-regulated or up-regulated 276 and 186
genes, respectively, by z2-fold. Interestingly, a synthetic pyrrole-
imidazole polyamide that inhibits in a sequence-specific fashion
HIF binding to the HRE of the VEGF promoter (44) caused 264
Table 1. Selected list of HIF-1-inducible genes down-regulated by NSC-13502 (20 nmol/L) in U251 cells cultured under
hypoxia conditions
Genbank accession no. Annotated genes HRE Log2 value of ratio change
Hypoxia NSC-13502 + hypoxia
AF022375 VEGF TACGTG 1.6 2.8
NM_000598 IGFBP3 ND* 4.0 3.9
X60673 AK3 TGCGTG 2.1 3.1
AY886764 BNIP3 CG/ACGTG 1.9 3.6
NM_004331 BNIP3L ND 1.5 1.6
NM_019058 DDIT4 TACGTG 2.9 4.4
NM_014367 E2IG5 GGCGTG 2.2 3.1
NM_001956 EDN2 ND 1.5 2.2
NM_000158 GBE1 ND 1.7 3.3
NM_006096 NDRG1 ND 3.8 4.4
NM_004567 PFKFB4 CGCGTG 1.8 2.8
NM_001216 CA9 TACGTG 1.5 2.2
NM_001124 ADM AACGTG 2.3 2.7
BC093742 HIG2 ND 3.3 4.6
*ND, not determined.
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and 73 genes to be down-regulated and up-regulated by 2-fold,
respectively, at a concentration of 1 Amol/L.
NSC-13502 was brought into clinical trials by the NCI 20 years
ago based on its antitumor activity against two i.p. implanted
murine tumors, the B16 melanoma and the P388 leukemia (47).
NSC-13502, at 1.2 to 1.5 mg/m2 once weekly for 4 weeks or once
every 3 to 4 weeks (47–50), has been extensively tested in phase I-II
clinical trials. Nausea, vomiting, reversible liver enzyme abnormal-
ities, and allergic reactions were the most common toxicities
encountered. However, minimal or no antitumor activity was found
in phase II clinical trials. It remains to be established if, based on
evidence presented in this article, alternative schedules of
administration of NSC-13502 aimed at inhibiting HIF-1 activity
might have a better therapeutic potential. Further experiments will
determine whether this is a feasible approach to modulate HIF-1–
dependent gene expression in vivo and to explore its potential
therapeutic applications.
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